Leading life sciences venture firm Sofinnova Partners entered into a long-term strategic and financial partnership with Apollo, a high-growth, alternative asset manager looking to expand its presence in the life sciences.
In recent months, the biotech and biopharma industries have been struggling with layoffs and dropping stocks. However, some companies are still experiencing success. Sanofi, AstraZeneca, Avillion and Diadem recently announced positive clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
The COVID-19 pandemic has had a significant impact on the biopharma industry. From artificial intelligence breakthroughs to at-home genetic testing, BioSpace reviews some of the ways COVID-19 has changed the industry and what we may see in the near future.
NRx Pharmaceuticals filed a counter lawsuit against Relief Therapeutics, the company it initially partnered with to develop the experimental COVID-19 treatment aviptadil, which was submitted to the U.S. Food and Drug Administration for Emergency Use Authorization.
Dr. Bethany Valente, founder and managing partner of Tempo7 LLC, discusses the challenges that biotech and pharma-based businesses face as they work to create more efficient development time frames for product, therapy, or drug development. Dr. Valente says open innovation helps in resolving some of these challenges.
Biopharma and life sciences companies strengthened their leadership teams and boards with these personnel appointments.
Companies across the biotech and biopharma industries reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.
BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Three biopharma companies recently shuttered their clinical programs after either their drug compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints.
Eli Lilly, Johnson & Johnson and GlaxoSmithKline headline the second annual edition of the Outcomes Creativity Index (OCI), a ranking of pharmaceutical companies and prescription brands according to creativity and innovation. The OCI is an aggregate score-based creative achievement encompassing results from eight leading U.S. and international healthcare awards shows that are tabulated to rank the top 10 pharmaceutical companies and top 10 prescription brands.
